Purpose: Antipsychotic long-acting injections (AP-LAIs) are indicated for patients affected by schizophrenia especially those with poor treatment adherence. Patients and Methods: To compare paliperidone palmitate 3-monthly (PP3M), paliperidone palmitate one-monthly (PP1M) and haloperidol decanoate (HAL-D) treatment, we enrolled 90 patients with schizophrenia treated in Mental Health Center with one of the three AP-LAIs for at least six months and followed them for another 6 months. At 6 and 12 months of treatment we administered Clinical Global Impression-Severity, Global Assessment of Functioning and World Health Organization Quality of Life-26 items (WHOQOL-BREF). At 1-year treatment, we evaluated relapses (psychiatric hospitalizations and urgent consultations), side effects and drop-outs. Results: We did not highlight any statistically significant difference among the three treatments in relapses and scale scores. Weight increase was significantly higher in PP1M and PP3M groups. Twelve patients (13.3%) discontinued AP-LAI. At 1-year AP-LAI treatment, 69% of patients rated quality of life as “good” or “very good” and 71% declared themselves to be “satisfied” or “very satisfied”. Conclusion: HAL-D, PP1M and PP3M 1-year treatments were similarly effective in preventing relapses and improving quality of life and health satisfaction. All discontinuations in the new 3-monthly antipsychotic treatment were caused by patient refusal to continue it.
Effectiveness and Quality of Life with Paliperidone Palmitate 3-Monthly in Comparison with Other Long-Acting Drugs / Di Lorenzo, Rosaria; Iorio, Anita; Pinelli, Margherita; Magarini, Federica Maria; Marchi, Mattia; Sacchetti, Andrea; Calogero, Chiara; Galeazzi, Gian Maria; Ferri, Paola; Rovesti, Sergio; Minarini, Alessandro. - In: NEUROPSYCHIATRIC DISEASE AND TREATMENT. - ISSN 1178-2021. - 18:(2022), pp. 829-846. [10.2147/NDT.S356341]
Data di pubblicazione: | 2022 | |
Data di prima pubblicazione: | 12-apr-2022 | |
Titolo: | Effectiveness and Quality of Life with Paliperidone Palmitate 3-Monthly in Comparison with Other Long-Acting Drugs | |
Autore/i: | Di Lorenzo, Rosaria; Iorio, Anita; Pinelli, Margherita; Magarini, Federica Maria; Marchi, Mattia; Sacchetti, Andrea; Calogero, Chiara; Galeazzi, Gian Maria; Ferri, Paola; Rovesti, Sergio; Minarini, Alessandro | |
Autore/i UNIMORE: | ||
Digital Object Identifier (DOI): | http://dx.doi.org/10.2147/NDT.S356341 | |
Rivista: | ||
Volume: | 18 | |
Pagina iniziale: | 829 | |
Pagina finale: | 846 | |
Codice identificativo ISI: | WOS:000789105800001 | |
Codice identificativo Scopus: | 2-s2.0-85129084353 | |
Citazione: | Effectiveness and Quality of Life with Paliperidone Palmitate 3-Monthly in Comparison with Other Long-Acting Drugs / Di Lorenzo, Rosaria; Iorio, Anita; Pinelli, Margherita; Magarini, Federica Maria; Marchi, Mattia; Sacchetti, Andrea; Calogero, Chiara; Galeazzi, Gian Maria; Ferri, Paola; Rovesti, Sergio; Minarini, Alessandro. - In: NEUROPSYCHIATRIC DISEASE AND TREATMENT. - ISSN 1178-2021. - 18:(2022), pp. 829-846. [10.2147/NDT.S356341] | |
Tipologia | Articolo su rivista |
File in questo prodotto:
File | Descrizione | Tipologia | |
---|---|---|---|
NDT-356341-effectiveness-and-quality-of-life-with-paliperidone-palmitat.pdf | Articolo principale | Versione dell'editore (versione pubblicata) | Open Access Visualizza/Apri |
Pubblicazioni consigliate

I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris